<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p17" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_17{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t2_17{left:341px;bottom:30px;}
#t3_17{left:348px;bottom:25px;letter-spacing:0.11px;}
#t4_17{left:377px;bottom:30px;}
#t5_17{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t6_17{left:540px;bottom:30px;}
#t7_17{left:546px;bottom:25px;letter-spacing:0.07px;}
#t8_17{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#t9_17{left:44px;bottom:63px;letter-spacing:0.1px;}
#ta_17{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#tb_17{left:285px;bottom:827px;letter-spacing:-0.25px;}
#tc_17{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_17{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_17{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_17{left:1109px;bottom:28px;letter-spacing:0.23px;}
#tg_17{left:37px;bottom:181px;}
#th_17{left:47px;bottom:176px;letter-spacing:0.13px;}
#ti_17{left:262px;bottom:176px;}
#tj_17{left:37px;bottom:165px;}
#tk_17{left:43px;bottom:159px;letter-spacing:0.11px;word-spacing:0.01px;}
#tl_17{left:46px;bottom:142px;letter-spacing:0.12px;}
#tm_17{left:46px;bottom:125px;letter-spacing:0.13px;}
#tn_17{left:37px;bottom:114px;}
#to_17{left:48px;bottom:108px;letter-spacing:0.13px;word-spacing:-0.06px;}
#tp_17{left:333px;bottom:108px;}
#tq_17{left:36px;bottom:748px;letter-spacing:0.48px;}
#tr_17{left:36px;bottom:729px;letter-spacing:0.25px;}
#ts_17{left:186px;bottom:748px;letter-spacing:0.32px;word-spacing:-0.31px;}
#tt_17{left:687px;bottom:748px;letter-spacing:0.28px;word-spacing:-0.12px;}
#tu_17{left:1078px;bottom:553px;letter-spacing:-0.09px;}
#tv_17{left:1078px;bottom:535px;letter-spacing:-0.06px;}
#tw_17{left:1078px;bottom:516px;letter-spacing:-0.08px;}
#tx_17{left:1078px;bottom:498px;letter-spacing:-0.1px;}
#ty_17{left:1078px;bottom:480px;letter-spacing:-0.25px;}
#tz_17{left:36px;bottom:465px;letter-spacing:-0.1px;}
#t10_17{left:36px;bottom:447px;letter-spacing:-0.11px;}
#t11_17{left:192px;bottom:695px;letter-spacing:-0.1px;}
#t12_17{left:192px;bottom:677px;letter-spacing:-0.09px;}
#t13_17{left:192px;bottom:658px;letter-spacing:-0.09px;}
#t14_17{left:192px;bottom:640px;letter-spacing:-0.13px;}
#t15_17{left:215px;bottom:647px;letter-spacing:-0.13px;}
#t16_17{left:192px;bottom:614px;letter-spacing:-0.1px;}
#t17_17{left:192px;bottom:435px;letter-spacing:-0.1px;}
#t18_17{left:192px;bottom:576px;letter-spacing:-0.09px;}
#t19_17{left:192px;bottom:557px;letter-spacing:-0.09px;}
#t1a_17{left:192px;bottom:539px;letter-spacing:-0.08px;}
#t1b_17{left:192px;bottom:521px;letter-spacing:-0.08px;}
#t1c_17{left:192px;bottom:502px;letter-spacing:-0.1px;}
#t1d_17{left:275px;bottom:510px;letter-spacing:-0.09px;}
#t1e_17{left:192px;bottom:389px;letter-spacing:-0.09px;}
#t1f_17{left:192px;bottom:371px;letter-spacing:-0.1px;}
#t1g_17{left:192px;bottom:352px;letter-spacing:-0.09px;}
#t1h_17{left:288px;bottom:360px;letter-spacing:-0.13px;}
#t1i_17{left:192px;bottom:334px;letter-spacing:-0.1px;word-spacing:-0.06px;}
#t1j_17{left:313px;bottom:342px;}
#t1k_17{left:192px;bottom:316px;letter-spacing:-0.09px;}
#t1l_17{left:192px;bottom:297px;letter-spacing:-0.1px;}
#t1m_17{left:281px;bottom:305px;letter-spacing:-0.13px;}
#t1n_17{left:192px;bottom:264px;letter-spacing:-0.1px;}
#t1o_17{left:192px;bottom:232px;letter-spacing:-0.08px;}
#t1p_17{left:383px;bottom:614px;letter-spacing:-0.1px;}
#t1q_17{left:383px;bottom:595px;letter-spacing:-0.09px;}
#t1r_17{left:538px;bottom:603px;}
#t1s_17{left:384px;bottom:474px;letter-spacing:-0.1px;}
#t1t_17{left:384px;bottom:456px;letter-spacing:-0.09px;}
#t1u_17{left:384px;bottom:437px;letter-spacing:-0.09px;}
#t1v_17{left:450px;bottom:445px;}
#t1w_17{left:525px;bottom:558px;letter-spacing:-0.09px;}
#t1x_17{left:525px;bottom:539px;letter-spacing:-0.1px;}
#t1y_17{left:525px;bottom:521px;letter-spacing:-0.08px;}
#t1z_17{left:525px;bottom:503px;letter-spacing:-0.11px;}
#t20_17{left:521px;bottom:426px;letter-spacing:-0.08px;}
#t21_17{left:521px;bottom:407px;letter-spacing:-0.09px;}
#t22_17{left:687px;bottom:530px;letter-spacing:-0.1px;}
#t23_17{left:854px;bottom:538px;letter-spacing:-0.12px;}
#t24_17{left:687px;bottom:435px;letter-spacing:-0.13px;}
#t25_17{left:709px;bottom:442px;}
#t26_17{left:687px;bottom:416px;letter-spacing:-0.06px;}
#t27_17{left:687px;bottom:398px;letter-spacing:-0.1px;}
#t28_17{left:854px;bottom:406px;letter-spacing:-0.12px;}
#t29_17{left:687px;bottom:605px;letter-spacing:-0.13px;}
#t2a_17{left:710px;bottom:613px;}
#t2b_17{left:940px;bottom:681px;letter-spacing:-0.09px;}
#t2c_17{left:940px;bottom:663px;letter-spacing:-0.09px;}
#t2d_17{left:1006px;bottom:663px;letter-spacing:-0.25px;}
#t2e_17{left:940px;bottom:349px;letter-spacing:-0.09px;}
#t2f_17{left:940px;bottom:330px;letter-spacing:-0.09px;}
#t2g_17{left:1006px;bottom:330px;letter-spacing:-0.25px;}
#t2h_17{left:588px;bottom:181px;}
#t2i_17{left:598px;bottom:176px;letter-spacing:0.12px;word-spacing:-0.03px;}
#t2j_17{left:1108px;bottom:176px;}
#t2k_17{left:588px;bottom:165px;}
#t2l_17{left:598px;bottom:159px;letter-spacing:0.12px;}
#t2m_17{left:596px;bottom:142px;letter-spacing:0.08px;word-spacing:0.04px;}
#t2n_17{left:596px;bottom:125px;letter-spacing:0.12px;}
#t2o_17{left:1018px;bottom:125px;letter-spacing:0.13px;}
#t2p_17{left:1102px;bottom:125px;}
#t2q_17{left:588px;bottom:114px;}
#t2r_17{left:598px;bottom:108px;letter-spacing:0.12px;}
#t2s_17{left:629px;bottom:108px;letter-spacing:0.12px;}
#t2t_17{left:707px;bottom:108px;letter-spacing:0.08px;word-spacing:0.05px;}
#t2u_17{left:36px;bottom:778px;letter-spacing:-0.15px;word-spacing:0.06px;}
#t2v_17{left:388px;bottom:683px;letter-spacing:-0.1px;}
#t2w_17{left:388px;bottom:663px;letter-spacing:-0.09px;}
#t2x_17{left:384px;bottom:351px;letter-spacing:-0.1px;}
#t2y_17{left:384px;bottom:331px;letter-spacing:-0.09px;}
#t2z_17{left:935px;bottom:536px;letter-spacing:-0.1px;}
#t30_17{left:935px;bottom:518px;letter-spacing:-0.09px;}
#t31_17{left:935px;bottom:500px;letter-spacing:-0.08px;}
#t32_17{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_17{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s1_17{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s2_17{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_17{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_17{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_17{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_17{font-size:12px;font-family:ArialMT_5tg;color:#000;}
.s7_17{font-size:15px;font-family:ArialMT_5tg;color:#0065A4;}
.s8_17{font-size:15px;font-family:ArialMT_5tg;color:#000;}
.s9_17{font-size:17px;font-family:Arial-BoldMT_5te;color:#0065A4;}
.sa_17{font-size:14px;font-family:Arial-BoldMT_5te;color:#000;}
.sb_17{font-size:14px;font-family:Arial-BoldMT_jz;color:#000;}
.sc_17{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts17" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_jz;
	src: url("fonts/Arial-BoldMT_jz.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg17Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg17" style="-webkit-user-select: none;"><object width="1210" height="935" data="17/17.svg" type="image/svg+xml" id="pdf17" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_17" class="t s0_17">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_17" class="t s1_17">® </span>
<span id="t3_17" class="t s0_17">(NCCN </span>
<span id="t4_17" class="t s1_17">® </span>
<span id="t5_17" class="t s0_17">), All rights reserved. NCCN Guidelines </span>
<span id="t6_17" class="t s1_17">® </span>
<span id="t7_17" class="t s0_17">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_17" class="t s2_17">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="t9_17" class="t s2_17">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="ta_17" class="t s3_17">NCCN Guidelines Version 4.2024 </span>
<span id="tb_17" class="t s3_17">Cancer of the Oropharynx (p16-negative) </span>
<span id="tc_17" class="t s4_17">NCCN Guidelines Index </span>
<span id="td_17" class="t s4_17">Table of Contents </span>
<span id="te_17" class="t s4_17">Discussion </span>
<span id="tf_17" class="t s5_17">ORPH-3 </span>
<span id="tg_17" class="t s6_17">k </span>
<span id="th_17" class="t s7_17">Principles of Surgery (SURG-A)</span><span id="ti_17" class="t s8_17">. </span>
<span id="tj_17" class="t s6_17">l </span>
<span id="tk_17" class="t s8_17">Tumors in the base of tongue, posterior pharyngeal wall, and soft palate </span>
<span id="tl_17" class="t s8_17">require consideration of bilateral neck treatment as do tumors of the tonsil </span>
<span id="tm_17" class="t s8_17">invading the tongue base. </span>
<span id="tn_17" class="t s6_17">n </span>
<span id="to_17" class="t s7_17">Principles of Radiation Therapy (ORPH-A)</span><span id="tp_17" class="t s8_17">. </span>
<span id="tq_17" class="t s5_17">CLINICAL </span>
<span id="tr_17" class="t s5_17">STAGING </span>
<span id="ts_17" class="t s5_17">TREATMENT OF PRIMARY AND NECK </span><span id="tt_17" class="t s5_17">ADJUVANT TREATMENT </span>
<span id="tu_17" class="t s5_17">Recurrent </span>
<span id="tv_17" class="t s5_17">or </span>
<span id="tw_17" class="t s5_17">persistent </span>
<span id="tx_17" class="t s5_17">disease </span>
<span id="ty_17" class="t s9_17">(ADV-3) </span>
<span id="tz_17" class="t s5_17">p16-negative </span>
<span id="t10_17" class="t s5_17">T3–4a,N0–1 </span>
<span id="t11_17" class="t s5_17">Concurrent </span>
<span id="t12_17" class="t s5_17">systemic </span>
<span id="t13_17" class="t s5_17">therapy/ </span>
<span id="t14_17" class="t s5_17">RT </span>
<span id="t15_17" class="t sa_17">n,o </span>
<span id="t16_17" class="t s5_17">or </span>
<span id="t17_17" class="t s5_17">or </span>
<span id="t18_17" class="t s5_17">Resection of </span>
<span id="t19_17" class="t s5_17">primary and </span>
<span id="t1a_17" class="t s5_17">ipsilateral or </span>
<span id="t1b_17" class="t s5_17">bilateral neck </span>
<span id="t1c_17" class="t s5_17">dissection </span>
<span id="t1d_17" class="t sa_17">k,l </span>
<span id="t1e_17" class="t s5_17">Induction </span>
<span id="t1f_17" class="t s5_17">chemotherapy </span>
<span id="t1g_17" class="t s5_17">(category 3) </span>
<span id="t1h_17" class="t sb_17">o,q </span>
<span id="t1i_17" class="t s5_17">followed by RT </span>
<span id="t1j_17" class="t sa_17">n </span>
<span id="t1k_17" class="t s5_17">or systemic </span>
<span id="t1l_17" class="t s5_17">therapy/RT </span>
<span id="t1m_17" class="t sa_17">n,o </span>
<span id="t1n_17" class="t s5_17">or </span>
<span id="t1o_17" class="t s5_17">Clinical trials </span>
<span id="t1p_17" class="t s5_17">No adverse </span>
<span id="t1q_17" class="t s5_17">pathologic features </span>
<span id="t1r_17" class="t sa_17">p </span>
<span id="t1s_17" class="t s5_17">Adverse </span>
<span id="t1t_17" class="t s5_17">pathologic </span>
<span id="t1u_17" class="t s5_17">features </span>
<span id="t1v_17" class="t sa_17">p </span>
<span id="t1w_17" class="t s5_17">Extranodal </span>
<span id="t1x_17" class="t s5_17">extension and/ </span>
<span id="t1y_17" class="t s5_17">or positive </span>
<span id="t1z_17" class="t s5_17">margin </span>
<span id="t20_17" class="t s5_17">Other risk </span>
<span id="t21_17" class="t s5_17">features </span>
<span id="t22_17" class="t s5_17">Systemic therapy/RT </span>
<span id="t23_17" class="t sa_17">n,o </span>
<span id="t24_17" class="t s5_17">RT </span>
<span id="t25_17" class="t sa_17">n </span>
<span id="t26_17" class="t s5_17">or </span>
<span id="t27_17" class="t s5_17">Systemic therapy/RT </span>
<span id="t28_17" class="t sa_17">n,o </span>
<span id="t29_17" class="t s5_17">RT </span>
<span id="t2a_17" class="t sa_17">n </span>
<span id="t2b_17" class="t s5_17">Recurrent or persistent </span>
<span id="t2c_17" class="t s5_17">disease </span><span id="t2d_17" class="t s9_17">(ADV-3) </span>
<span id="t2e_17" class="t s5_17">Recurrent or persistent </span>
<span id="t2f_17" class="t s5_17">disease </span><span id="t2g_17" class="t s9_17">(ADV-3) </span>
<span id="t2h_17" class="t s6_17">o </span>
<span id="t2i_17" class="t s7_17">Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)</span><span id="t2j_17" class="t s8_17">. </span>
<span id="t2k_17" class="t s6_17">p </span>
<span id="t2l_17" class="t s8_17">Adverse pathologic features: extranodal extension, positive margins, close margins, </span>
<span id="t2m_17" class="t s8_17">pT3 or pT4 primary, pN2 or pN3 nodal disease, nodal disease in levels IV or V, </span>
<span id="t2n_17" class="t s8_17">perineural invasion, vascular invasion, and lymphatic invasion </span><span id="t2o_17" class="t s7_17">(Discussion)</span><span id="t2p_17" class="t s8_17">. </span>
<span id="t2q_17" class="t s6_17">q </span>
<span id="t2r_17" class="t s8_17">See </span><span id="t2s_17" class="t s7_17">Discussion </span><span id="t2t_17" class="t s8_17">on induction chemotherapy. </span>
<span id="t2u_17" class="t s5_17">Base of Tongue/Tonsil/Posterior Pharyngeal Wall/Soft Palate </span>
<span id="t2v_17" class="t s9_17">Post Systemic Therapy/RT or RT </span>
<span id="t2w_17" class="t s9_17">Neck Evaluation (FOLL-A, 2 of 2) </span>
<span id="t2x_17" class="t s9_17">Post Systemic Therapy/RT or RT </span>
<span id="t2y_17" class="t s9_17">Neck Evaluation (FOLL-A, 2 of 2) </span>
<span id="t2z_17" class="t s9_17">Follow-up </span>
<span id="t30_17" class="t s9_17">(FOLL-A, 1 </span>
<span id="t31_17" class="t s9_17">of 2) </span>
<span id="t32_17" class="t sc_17">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
